OH
Therapeutic Areas
Agomab Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ontunisertib (AGMB-129) | Fibrostenotic Crohn's Disease | Phase 1 |
| AGMB-447 | Not Specified | Not Disclosed |
| AGMB-101 | Not Specified | Not Disclosed |
Leadership Team at Agomab Therapeutics
TK
Tim Knotnerus
Chief Executive Officer
PW
Philippe Wiesel
Chief Medical Officer
AS
Andrea Sáez
Chief Development Officer
PK
Pierre Kemula
Chief Financial Officer
PV
Paul van der Horst
Chief Business Officer
EL
Ellen Lefever
General Counsel
DE
David Epstein
Chairman of the Board
AJ
Angelika Jahreis
Non-Executive Director
CB
Colin Bond
Non-Executive Director and Chairman of the Audit Committee
FV
Felice Verduyn-van Weegen
Non-Executive Director (Representing EQT Life Sciences)